PrecisionLife, Sano Genetics partner on studying long COVID

By The Science Advisory Board staff writers

May 12, 2022 -- PrecisionLife is joining forces with Sano Genetics to better understand the long-term effects of the coronavirus (long COVID). PrecisionLife’s proprietary combinatorial analytics platform will identify risk factors and potential drug targets by analyzing Sano Genetics’ data from 3,000 U.K. adults suffering from long COVID symptoms.

In particular, the new study seeks to determine why some people, even those with mild original COVID infections, are at risk of developing debilitating long COVID symptoms. The researchers also aim to discover novel drug targets and drug repositioning candidates with associated patient stratification biomarkers that could lead to new treatments for long COVID sufferers.

The partnership builds on support Sano Genetics received last year from the U.K. government funding body Innovate U.K. to anonymously gather genomic DNA data and patient-reported outcomes from 3,000 U.K. adults suffering from long COVID symptoms.

PrecisionLife announces series A financing
PrecisionLife closed its first series A investment round. The financing will enable the expansion and progression of the company's pipeline of commercial...
AI drug development startups raised $2.1B in 1st half of 2021
The market for artificial intelligence (AI) in drug development and discovery has been red-hot in recent years. The potential impact that AI can offer...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter